Budesonide in Crohn's disease: Findings of a compassionate-use program
Background/Aims: Budesonide controlled-release (CR) capsules are effective for inducing remission of Crohn's disease (CD) and are associated with fewer side effects than conventional corticosteroids. A compassionate-use program was implemented in countries where this treatment was unavailable. This paper reports the findings of this program. Methodology: Physicians were allowed to apply to AstraZe
